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Introduction {#sec1}
============

Despite recent advances in prevention and management, myelosuppression and febrile neutropenia remains one of the most disturbing complications of cancer therapies and common cause of morbidity and mortality, especially in pediatric cancer patients ([@bib2], [@bib20]). In pioneering studies, correcting neutropenia with granulocyte transfusion was shown to be efficient in the clinical management of septicemia ([@bib11]). Although recent clinical trials produced inconclusive evidence concerning its efficiency, granulocyte transfusion is still perceived as a life-saving support in neutropenic patients, especially in pediatric patients resistant to antimicrobial therapies ([@bib10], [@bib12], [@bib31], [@bib34]). However, the complicated logistics of granulocyte collection, the need for pre-treating donors with granulocyte colony-stimulating factor (G-CSF) or steroids, difficulties in collecting a sufficient number of good quality granulocytes and the limited storage time (24 h); all hamper the utility of granulocyte transfusion for correcting neutropenia, and may contribute to the inconclusive results observed in clinical trials.

Human induced pluripotent stem cells (hiPSCs) offer the potential to serve as a versatile and scalable source of granulocytes. Although our group and others have demonstrated the feasibility of neutrophil generation from hiPSCs ([@bib5], [@bib18], [@bib24], [@bib29], [@bib30]), previously described methods rely on the use of serum, feeder, or embryoid body formation, which hampers their adoption for good manufacturing practice (GMP) standards and clinical use. In present studies, we have developed a three-step protocol for efficient neutrophil production from hiPSCs in 2D serum- and feeder-free conditions using direct programming with modified mRNA (mmRNA), which is less immunogenic and more stable form of mRNA ([@bib1], [@bib27]). Initially, hiPSCs are directly programmed into hematoendothelial progenitors using ETV2 mmRNA, which then differentiated into myeloid progenitors in the presence of granulocyte-macrophage (GM)-CSF, fibroblast growth factor 2 (FGF2), and UM171. Myeloid progenitors could be continuously collected from cultures every 8--10 days for up to 30 days after ETV2 transfection, and subsequently differentiated into mature neutrophils in the presence of G-CSF and the retinoic acid agonist Am580. This method significantly expedites generation of neutrophils, with the first batch of neutrophils available as soon as 14 days after initiation of differentiation and allows the generation of up to 1.7 × 10^7^ neutrophils from 10^6^ hiPSCs. The proposed differentiation system may be suitable for generating mature functional granulocytic cells for correction of neutropenia. When coupled with genetic engineering technologies, this protocol can be also used to interrogate the role of genes involved in neutrophil development and function.

Results {#sec2}
=======

Induction of Hematoendothelial Program with Myeloid Potential by ETV2 mmRNA {#sec2.1}
---------------------------------------------------------------------------

Previously, we demonstrated that overexpressing transcription factors ETV2 and GATA2 is sufficient to induce a pan-myeloid program in hiPSCs, which proceeds through a hemogenic endothelium (HE) stage ([@bib7]). Although we have found that constitutive overexpression of ETV2 using lentiviral vectors induces predominantly non-hemogenic endothelium, we also noted that ETV2 induces GATA2 expression in hPSCs and very few HE with macrophage potential ([@bib7]). In addition, our recent studies suggest that molecular mechanisms upstream of GATA2 are sufficient to specify hematoendothelial programs in hPSCs, while GATA2 is required for endothelial-to-hematopoietic transition ([@bib15]). Given these findings and studies demonstrating the critical role of ETV2 threshold for hematoendothelial commitment ([@bib38]) and obligatory downregulation of ETV2 during subsequent stages of hematopoietic development in the embryo ([@bib13]), we explored whether transitional expression of ETV2 with mmRNA alone is sufficient for hematoendothelial programming in hiPSCs. For ETV2 mmRNA production we used a transcription template which contains a single 5′ UTR and a single 3′ UTR from the β globin gene. In previous studies, we found that mmRNA in this configuration provide maximum protein levels in hPSCs ([@bib27]). Overexpression of mmETV2 following culture of transfected hiPSCs in Stemline II serum-free medium with FGF2, rapidly induces CD144^+^-expressing endothelial cells that, on addition of GM-CSF, form floating CD43^+^ blood cells, most of which co-express CD45 ([Figures 1](#fig1){ref-type="fig"}A--1E). Transfection of cells with GFP or GATA2 mmRNA could not induce hematopoietic programming in these conditions, indicating that this effect is specific for ETV2 and is not an artifact of the mmRNA transfection procedure ([Figure S1](#mmc1){ref-type="supplementary-material"}). Interestingly, as soon as the first floating cells appeared (starting on day 5 after ETV2 treatment), some of them began to adhere and continue producing floating blood cells for another 2 weeks ([Figure 1](#fig1){ref-type="fig"}B), thereby allowing for continuous collection of blood cells for up to 3 weeks of culture. Typically, around 0.9 × 10^6^, 1.25 × 10^7^, and 2 × 10^6^ floating blood cells can be collected after the first, second, and third weeks, accordingly from 10^6^ hiPSCs transfected with ETV2 ([Figure 1](#fig1){ref-type="fig"}F).Figure 1Induction of a Hematoendothelial Program Following Transfection hiPSCs with ETV2 mmRNA(A) Schematic diagram of optimized protocol used for generation of neutrophils from hiPSCs in serum-, xeno-, and feeder-free conditions.(B) Representative light microscopy images showing hematoendothelial development following transfection IISH2i-BM9 hiPSCs with ETV2 mmRNA and culture with FGF2 and GM-CSF. Scale bars, 300 μm.(C and D) Representative experiment showing kinetics of CD144 and CD43 expression (percentages (C) and flow cytometry dot plots (D) in cultures.(E) Expression of CD144, CD43, and CD45 on day 6, 8, and 9 after ETV2 transfection. Bars show mean ± SE for 3 independent experiments.(F) Yield of floating myeloid cells in step 2 cultures from 10^6^ undifferentiated hiPSCs. Bars show mean ± SE for 2 independent experiments.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

CD45^+^ cells generated in ETV2 mmRNA-induced cultures co-expressed CD34 and lacked expression of megakaryocytic and erythroid markers CD41 and CD235a ([Figure 2](#fig2){ref-type="fig"}A). They quickly acquired early myeloid progenitor marker CD33 with more than 80% of total cells in suspension were positive for CD34 and CD33 on days 5--8 of differentiation ([Figures 2](#fig2){ref-type="fig"}B and 2C). However, CD33 marker was gradually decreased while mature myeloid markers CD11b and CD16 gradually increased if floating cells are collected at later time points ([Figure 2](#fig2){ref-type="fig"}D). Collected floating cells displayed myeloid progenitor morphology on cytospins ([Figure 2](#fig2){ref-type="fig"}E) and possess GM- and M-colony-forming cell (CFC) potential ([Figure 2](#fig2){ref-type="fig"}F), thereby suggesting that the ETV2-induced program was mostly restricted to myelomonocytic cells. Kinetic analysis revealed that CFC potential of myeloid progenitors greatly increased from day 4 to 9, but gradually decreased afterward ([Figure 2](#fig2){ref-type="fig"}F).Figure 2Formation of Myeloid Progenitors in hiPSC Cultures Transfected with ETV2 mmRNA(A) Flow cytometric analysis of CD34, CD33, and CD235a/CD41a expression in ETV2 mmRNA-transfected IISH2i-BM9 cultures differentiated in the presence of GM-CSF and FGF2.(B) Representative experiment shows kinetics of CD34 and CD33 expression.(C) Bar graphs show proportion of CD34^+^ and CD34^−^ cells in floating fraction at indicated days of differentiation. Results are mean + SE for 3 experiments.(D) Kinetics of CD11b and CD16 expression in cells collected from step 2 cultures. Error bars are + SE for 3 experiments.(E) Cytopsin showing the morphology of the myeloid progenitors generated in cultures after 10 days of differentiation. Scale bar, 20 μm.(F) Colony-forming potential of myeloid progenitors formed in cultures. Bars show mean ± SE for 2 independent experiments performed in duplicates. Representative images of colonies formed by cells collected from step 2 cultures are shown. Scale bars, 790 μm.(G) Yield of floating cells from IISH2i-BM9 hiPSCs in the presence of different cytokine combinations and UM171. Bars show mean ± SE for 3 (GM-CSF, FGF, and UM171) or 2 (remaining combinations) independent experiments.(H) Effect of different cytokine combinations on phenotype of myeloid cells. GM is GM-CSF, FGF is FGF2, FLT is FLT3L, U is UM171. Error bars are ± SE for 3 experiments.

Next, we investigated the cytokine and growth factor requirements for optimal expansion of myeloid progenitors induced with ETV2. The presence of GM-CSF, which we identified as a the most critical factor for hPSC-derived myelomonocytic cells ([@bib5], [@bib6], [@bib26]), was necessary for efficient production of myeloid progenitors because its removal substantially decreased the number of floating hematopoietic cells in cultures ([Figure 2](#fig2){ref-type="fig"}G). Similarly, withdrawal of FGF2 reduced blood production in ETV2-induced cultures ([Figure 2](#fig2){ref-type="fig"}G). To test whether myeloid cell production can be improved with the use of other cytokines or small molecules, we tested the effects of FLT3L, SCF, and small-molecule UM171, which has been shown to stimulate expansion of human cord blood CD34^+^ cells *ex vivo* ([@bib8]) and hPSC-derived myeloid progenitors enriched in G-CFCs ([@bib21]). We have found that the presence of SCF and FLT3L slightly decreased the number of collected floating cells during differentiation, while UM171 had no significant effect on the number of hematopoietic cells. Flow cytometric analysis revealed no significant effect of studied cytokines and small molecules on myeloid cell phenotype in cultures ([Figure 2](#fig2){ref-type="fig"}H). Thus, we concluded that FGF2 and GM-CSF are the two most critical cytokines to support myeloid lineage development in ETV2 mmRNA-transfected hiPSCs.

Induction of Neutrophils from ETV2-Induced Myeloid Progenitors {#sec2.2}
--------------------------------------------------------------

To induce formation of neutrophils from myeloid progenitors, we cultured them in StemSpan H3000 medium with G-CSF and retinoic acid agonist Am580, which is known to promote neutrophil production from human somatic CD34^+^ cells ([@bib19]). After 7 days of culture in these conditions, we observed formation of cells with typical neutrophil phenotype and morphology ([Figures 3](#fig3){ref-type="fig"}A and 3B). Although myeloid progenitors produced some macrophages, they were adherent to the plate while the collected floating cells contained a population of highly enriched in neutrophils ([Figure 3](#fig3){ref-type="fig"}B). Phenotypic analysis revealed that most of the collected floating cells expressed CD11b, MPO, and CD182, and greater than 50% were CD16-positive and expressed lactoferrin. However, generated neutrophils expressed relatively low levels of CD66b and were lacking the CD10 marker, which are typically present on mature peripheral blood neutrophils ([Figure 3](#fig3){ref-type="fig"}A). Although the effect of UM171 on the output of myeloid progenitors in step 2 differentiation cultures was minimal, we noticed that cells from UM171-treated cultures generated much higher neutrophils in the final differentiation step compared with myeloid progenitors generated in cultures without UM171 ([Figure 3](#fig3){ref-type="fig"}C). As mentioned previously, following collection of floating cells from step 2 differentiation cultures, adherent cells continued to generate myeloid progenitors that could be collected for an additional 2 weeks. Although the number of floating cells increased more than 10-fold following the second collection (second week; [Figure 1](#fig1){ref-type="fig"}F), they produce fewer neutrophils as compared with myeloid progenitors collected at day 8 of differentiation ([Figure 3](#fig3){ref-type="fig"}D). During the third week of culture, the number of floating myeloid cells collected dramatically decreased, although they were still able to differentiate into neutrophils. Overall, combining total neutrophil output from myeloid progenitor cultures collected over a 3-week period, we were able to generate up to 1.7 × 10^7^ neutrophils from 10^6^ hiPSCs.Figure 3Induction of Neutrophil Formation from Myeloid Progenitors(A) Flow cytometric analysis of generated neutrophils. Plots show unstained control (red) and specific antibody (blue) histograms.(B) Cytospin showing the morphology of the generated neutrophils. Scale bars, 100 μm and 10 μm (insert).(C) Neutrophil yields from 10^6^ myeloid progenitors that were cultured with or without UM171 and collected on day 8 after ETV2 mmRNA transfection. Bars show mean ± SE for 3 (GM, FGF, and U) and 2 (GM and FGF) independent experiments.(D) Total number of neutrophils obtained from 10^6^ myeloid progenitors that were cultured with UM171 and collected at different days of after ETV2 mmRNA transfection. Bars show mean ± SE for 2 independent experiments.(E) Phagocytosis of pHrodo Green *E. coli* particles by neutrophils generated from IISH2i-BM9 hiPSCs. Solid red peaks on flow graphs are control cells incubated on ice with bio-particles, blue traces are cells containing acidified, fluorescent *E. coli* bio-particles from 37°C incubation. Bar graph is from 3 independent experiments showing percent of cells from 37°C incubation with phagocytosed acidified *E. coli* bio-particles. Bars show mean ± SE. Difference between iPSC and primary neutrophils is not statistically significant (p = 0.3134) as determined by unpaired t test.(F) Reactive oxygen species production of hiPSC-derived neutrophils compared with primary blood neutrophils at 90 min. Bar graph is from 3 independent experiments showing fold increase of 50 ng/mL PMA-treated cells over control-treated cells. Bars show mean ± SE. Difference between hiPSC versus primary neutrophils is not statistically significant (p = 0.7522) as determined by unpaired t test.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Functional Characterization Obtained from ETV2-Induced Myeloid Progenitors {#sec2.3}
--------------------------------------------------------------------------

Functional analysis revealed that ETV2-induced neutrophils phagocytose pHrodo *E. coli* particles, although we noticed the presence of a population of immature myeloid progenitors lacking phagocytic activity in *ex-vivo*-generated cellular products ([Figure 3](#fig3){ref-type="fig"}E). In addition, ETV2-induced neutrophils generated reactive oxygen species in response to treatment with phorbol esters (PMA) ([Figure 3](#fig3){ref-type="fig"}F) and demonstrated chemotactic migration to N-formyl-methionyl-leucyl-phenylalanine (fMLP) and interleukin-8 (IL-8) using microfluidic analysis ([Figures 4](#fig4){ref-type="fig"}A and 4B; [Videos S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, and [S3](#mmc4){ref-type="supplementary-material"}). Although, the chemotactic index is not as robust as compared with primary human neutrophils, ETV2-derived neutrophils demonstrated directed migration to both IL-8 and fMLP and improved chemotactic responses as compared with the neutrophil-like PLB-985 cells ([@bib3], [@bib23]). Finally, the ETV2-induced neutrophils also chemotaxed to and phagocytosed the live bacteria *Pseudomonas aeruginosa* ([Figure 4](#fig4){ref-type="fig"}C; [Video S4](#mmc5){ref-type="supplementary-material"}) and formed an extracellular fibril matrix composed of granule protein and chromatin, characteristic of neutrophil extracellular traps (NETs) on treatment with phorbol ester (100 nm PMA; [Figure 5](#fig5){ref-type="fig"}). Taken together, these findings demonstrate that ETV2-induced neutrophils demonstrate phagocytic, chemotactic, and signaling functions similar to primary human neutrophils.Figure 4Analysis of Migratory Potential of hiPSC-Derived Neutrophils(A) Images from 45-min time-lapse movies of hiPSC-derived neutrophils during chemotaxis to vehicle control, fMLP, or IL-8 on fibrinogen. Yellow lines showing automated cell tracking. Scale bars, 100 μm.(B) Quantification of chemotactic index and velocity of hiPSC neutrophils, showing significant differences of hiPSC neutrophils exposed to chemoattractant compared with treatment with vehicle control. p values for chemotactic index, control to IL-8 p = 0.0040, control to fMLP p \< 0.0001. p values for velocity, control to IL-8 p = 0.0404, control to fMLP p = 0.0009 as determined by unpaired t test. Primary blood neutrophils showing chemotactic and velocity values. Bars show mean ± SE from 3 independent experiments with technical replicates, but not biological replicates for statistical analysis.(C) Montage image from high-resolution time-lapse movie of hiPSC neutrophils migrating and phagocytosing *Pseudomonas aeruginosa*. Arrow indicates one point during the movie when the cell is targeting bacteria. Scale bars, 10 μm. All functional assays with hiPSC-derived neutrophils were performed on batches obtained from myeloid progenitors collected at 8 or 12 days after ETV2 transfection.See also [Videos S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, [S3](#mmc4){ref-type="supplementary-material"}, and [S4](#mmc5){ref-type="supplementary-material"}.Figure 5Neutrophil Extracellular Trap FormationMaximum intensity projections of hiPSC and primary blood (PB) neutrophils. Both show characteristic multi-lobed nuclei in blue and the azurophilic granule protein neutrophil elastase in green with control treatment. On treatment with 100 nM PMA both hiPSC and primary blood neutrophils form an extracellular fibril matrix composed of granule protein and chromatin, characteristic of neutrophil extracellular traps. Scale bars, 10 μm.

Video S1. Fig 4a hiPSC-Derived Neutrophils Random Migration

Video S2. Fig 4a hiPSC-Derived Neutrophils Chemotaxing to fMLP

Video S3. Fig 4a hiPSC-Derived Neutrophils Chemotaxing to IL-8

Video S4. Fig 4c hiPSC-Derived Neutrophils Migrating and Phagocytosing

Comparative Analysis of the Efficacy of the ETV2 mmRNA-Based Protocol for Neutrophil Induction from Different hiPSC Lines {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------

Two more hiPSC lines, bone marrow-derived iPSC (IISH1i-BM1) and fibroblast-derived iPSC (DF-19-9-7T) lines were assessed for their capacity of inducing neutrophils differentiation using ETV2 mmRNA. Both cell lines were successfully programmed to myeloid progenitors, although with different efficiencies. Thus, for IISH1i-BM1 and DF-19-9-7T cell lines programming efficiency to CD43^+^ cells were 84% and 44%, respectively. After terminal differentiation step, neutrophils exhibited the expected morphology ([Figure S2](#mmc1){ref-type="supplementary-material"}).

Discussion {#sec3}
==========

In this study we developed a simple and efficient method for generating neutrophils from hiPSCs by triggering the myeloid hematoendothelial program with ETV2 mmRNA, subsequently inducing and expanding myeloid progenitors, and finally differentiating them into neutrophils. This methods allows for neutrophil production in GMP-compatible conditions without feeder cells, or serum and xenogenic components. The first batch of neutrophils can be obtained within a very short period of time (14 days after hiPSC transfection with ETV2 mmRNA). Because myeloid progenitors generated from ETV2 mmRNA-transfected cells continue generating neutrophil precursors for up to 3 weeks of culture in the presence of GM-CSF, FGF2, and UM171, they can be collected weekly and used to produce neutrophils. This allows for total collection of up to 1.7 × 10^7^ neutrophils from 10^6^ hiPSCs. The method described here is based on a 2D culture system and is easily amendable to robotic manufacturing. Although neutrophils produced by this method had the capacity to produce reactive oxygen species, migrate in response to fMLP and IL-8, phagocytose bacteria, and form NETs, they were somewhat different from peripheral blood neutrophils and neutrophils produced from hPSCs in the presence of serum and feeders in our previous studies ([@bib5]). They had unique CD10-negative CD66b^low^ phenotype and displayed somewhat reduced *E. coli* phagocytosis activity. CD10 is expressed in segmented neutrophils. However, CD10 expression is reduced in peripheral blood neutrophils from newborn infants or persons treated with G-CSF ([@bib22], [@bib37]), while neutrophil activation with GM-CSF, tumor necrosis factor, or complement component 5a increases CD10 expression ([@bib17], [@bib33]). Thus, it is possible that lack of CD10 expression may be associated with the unique serum-free conditions we are using for their differentiation. It has become clear that, in addition to their phagocytic activities and their role in innate host defense, neutrophils contribute to the regulation of immune responses (reviewed in [@bib25]). Further detailed analysis of the function of hiPSC-derived neutrophils generated in our conditions is essential to determine whether their unique phenotype is associated with proinflammatory or immunosuppressive properties. Nevertheless, these cells will also provide a powerful tool to analyze pathways that regulate neutrophil function since, unlike primary human neutrophils, they are amenable to genetic manipulation and modeling of human disease mutations.

Successful generation of myeloid progenitors in our studies was achieved with ETV2 mmRNA. ETV2 belongs to the ETS family of transcription factors and is recognized as a master regulator of hematoendothelial fate, which is transiently expressed in specifying hematoendothelial progenitors ([@bib9], [@bib16], [@bib28]). ETV2 directly induces genes required for specification of hematopoietic and vascular cells including other ETS genes and GATA2 (reviewed in [@bib28]). In our present studies, we revealed that transient transfection of hiPSCs with ETV2 is sufficient to induce hematoendothelial progenitors that can be subsequently differentiated to neutrophils. Compared with classical differentiation methods, direct ETV2-mediated programming proceeds without transition through the mesodermal stage and requires a minimal numbers of growth factors (FGF2, GM-CFC, and G-CSF) to achieve neutrophil differentiation, thereby allowing for cost-efficient production of neutrophils. Although some additional developmental work is required to improve functionality of generated cells and adopt this protocol to bioreactor platform to enable clinical translation, the described method in conjunction with CRISPR/Cas9 gene editing technologies can already be used for disease modeling and interrogation of molecular mechanisms involved in neutrophil development and function.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

Bone marrow-derived IISH2i-BM9 and IISH1i-BM1 hiPSCs ([@bib14]) and fibroblast-derived DF-19-9-7T hiPSCs ([@bib36]) were obtained from WiCell (Madison, WI). hiPSCs were cultured on Matrigel-coated tissue culture plates in E8 medium (STEMCELL Technologies, Vancouver, Canada) ([@bib4]).

mmRNA Synthesis and Transfection {#sec4.2}
--------------------------------

Human ETV2 transcript variant 1 (NM_014209.3) was cloned into a 5′-MCS-1β construct as described previously ([@bib27]). To generate IVT templates with a 180-A tract, a reverse primer containing 180 T base pairs and an ATCGGTGCGGGCCTCTTCGCTA forward primer including T7 promoter were used in a PCR reaction. All PCR reactions were carried out using Phusion (Thermo Fisher Scientific). The mmRNA was synthesized using the MEGAscript T7 Kit (Ambion, Austin, TX), using a custom ribonucleoside cocktail comprised of 3′-0-Me-m7G(5′)ppp(5′)G ARCA cap analog, pseudouridine triphosphate (TriLink BioTechnologies, San Diego, CA), ATP, guanosine triphosphate, and cytidine triphosphate. The synthesis reactions were set up according to the manufacturer\'s instructions. Reactions were incubated for 2 h at 37°C and treated with DNAse. RNA was purified using a PureLink RNA Mini Kit (Thermo Fisher Scientific) and adjusted with RNase-free water to 100 ng/μL working concentration before being stored at −80°C. Undifferentiated hiPSCs were transfected with using TransIT-mRNA reagent in E8 medium containing ROCK inhibitor ([@bib27]). In brief, for transfection, single-cell suspension was prepared using HyQtase (Thermo Fisher Scientific). Per one well of transfection, a total of 2 × 10^5^ cells in 1 mL complete E8 medium with 10 μM ROCK inhibitor (STEMCELL Technologies) were plated into a collagen IV-coated 6-well plate; 30--60 min later, a mixture of 200 ng ETV2:TransIT-mRNA (Mirus Bio, Madison, WI) was added to each well according to the manufacturer\'s instructions.

Feeder-, Xeno-, and Serum-free Generation of Neutrophils from hiPSCs {#sec4.3}
--------------------------------------------------------------------

The day after transfection (day 1), the medium was changed with 1 mL of Stemline II (Sigma) supplemented with 20 ng/mL of human FGF2 (PeproTech). On day 2, 1 mL of the same medium was added. On day 3, the medium was changed and 1 mL of Stemline II supplemented with FGF2 (20 ng/mL), GM-CSF (25 ng/mL) (PeproTech), and UM171 (50 nM; Xcess Biosciences) were added. This medium was added daily up to days 8 to 12. On days 8 to 12, floating cells were gently harvested and used for terminal neutrophil differentiation. Following the first collection of floating cells, 2 mL of StemlineII supplemented with FGF2, GM-CSF, and UM171 was added to the remaining adherent cells. An additional 2 mL of the same medium was added every 2 days until the next round of floating cell collection on days 16 to 19. A similar procedure was followed for the third round of cell collection on days 23 to 29. To induce neutrophil terminal differentiation, floating cells were cultured in StemSpanH300 medium (STEMCELL Technologies), supplemented with GlutaMAX 100X (Thermo Fisher Scientific), ExCyte 0.2% (Merck Millipore), human G-CSF (150 ng/mL; Amgen), Am580 retinoic acid agonist 2.5 μM (Sigma-Aldrich), and gentamycin (1,000×) (Life Technologies) at 5 × 10^5^ cells/mL density. After 4 days, 2 mL of the same medium with all components and cytokines was added on the top of existing culture. Mature neutrophils were gently harvested from the supernatant after 6--8 days of culture, leaving the adherent macrophages, and filtered through a 70-μM mesh (Falcon, Life Sciences) before analysis.

Flow Cytometry {#sec4.4}
--------------

To analyze cell surface markers, 5 × 10^5^ cells were stained in fluorescence-activated cell sorting buffer with the appropriate antibodies ([Table S1](#mmc1){ref-type="supplementary-material"}). Ghost Dye (Tonbo Biosciences, San Diego, CA) was used to analyze the live cell population. For intracellular staining, cells were resuspended in Fixation Reagent (Medium A; Invitrogen) and incubated at room temperature for 15 min. After washing cells with PBS, cells were resuspended in 100 μL of Permeabilization Reagent (Medium B) (Invitrogen) and stained with Lactoferrin or MPO antibody ([Table S1](#mmc1){ref-type="supplementary-material"}) for 15 min. Cells were analyzed using a MACSQuant Analyzer 10 (Miltenyi Biotec, San Diego, CA) or Thermo Fisher Scientific Attune and FlowJo software (Tree Star, Ashland, OR).

Wright-Giemsa Staining {#sec4.5}
----------------------

To assess the morphology of cells within colonies, cells were fixed on glass slides using a Cytospin centrifuge (Cytospin 2; Thermo Shandon), stained with Wright-Giemsa solution (Sigma-Aldrich), and then observed under a light microscope (Olympus, Tokyo).

CFC Assay {#sec4.6}
---------

Total cells were collected daily from days 4 to 10, and floating cells from day 14 cultures were subjected to hematopoietic clonogenic assay. Colony assays were performed using serum-containing MethoCult H4435 (STEMCELL Technologies) in 35-mm low-adherent culture dishes (STEMCELL Technologies) according to the manufacture\'s protocol. Colony types were evaluated after 14 days of incubation at 37°C, 5% CO~2~ by inverted light microscopy (Olympus).

Chemotaxis Assay {#sec4.7}
----------------

Chemotaxis was assessed using a microfluidic device as described previously ([@bib35]). In brief, polydimethylsiloxane devices were plasma treated and adhered to glass coverslips. Devices were coated with 10 μg/mL fibrinogen (Sigma) in PBS for 30 min at 37°C, 5% CO~2~. The devices were blocked with 2% BSA-PBS for 30 min at 37°C, 5% CO~2~, to block non-specific binding, and then washed twice with mHBSS. Cells were stained with calcein AM (Molecular Probes) in PBS for 10 min at room temperature followed by resuspension in modified Hank's balanced salt solution (mHBSS). Cells were seeded at 5 × 10^6^/mL to allow adherence for 30 min before addition of chemoattractant. Either 1 μM fMLP (Sigma) or 11.25 μM IL-8 (R&D Systems) was loaded onto the devices. Cells were imaged for 45--90 min every 30 s on a Nikon Eclipse TE300 inverted fluorescent microscope with a 10× objective and an automated stage using MetaMorph software (Molecular Devices). Automated cell tracking analysis was done using JEX software ([@bib32]) to calculate chemotactic index and velocity.

Phagocytosis {#sec4.8}
------------

Phagocytosis was assessed using pHrodo Green *E. coli* BioParticles Conjugate (Invitrogen) according to a modified manufacturer\'s protocol. pHrodo Green *E. coli* beads were resuspended in 2 mL of PBS and sonicated with an ultrasonicator 3 times (20% amplitude, 20 s on/10 s off). Beads per assay (100 μL) were opsonized by mixing with opsonizing reagent at a 1:1 ratio and incubated at 37°C for 1 h. Beads were washed 3 times mHBSS buffer by centrifugation at 4°C, 1,500 RCF for 15 min then final resuspension in mHBSS buffer. Beads were used immediately or stored at 4°C for several days. Cells (5 × 10^5^) were resuspended in 100 μL of opsonized bead solution and incubated at 37°C or on ice for 1 h. Phagocytosis was stopped by placing all samples on ice. Analysis was carried out with Thermo Fisher Scientific Attune cytometer for fluorescent particles (509/533). Cells were gated based on granulocyte population, single cells, and live cells using propidium iodine.

Phagocytosis Imaging {#sec4.9}
--------------------

Overnight culture of *Pseudomonas aeruginosa* was diluted 1:4 and grown in LB at 37°C for about 2 h, or until a 1:100 dilution, OD~600~ of 0.3 was reached. Empirically determined, cells were diluted to 1,000 colony-forming units/nL, in our hands OD~600~ 2.5. hiPSC-derived neutrophils (2^5^) were mixed with 2^6^ bacteria in mHBSS and then plated on a glass coverslip coated with 10 μg/mL fibrinogen and imaged at 37°C on a Nikon Eclipse TE300 inverted fluorescent microscope with a 60× oil immersion objective and an automated stage using MetaMorph software.

Measurement of Reactive Oxygen Species Production in Neutrophils {#sec4.10}
----------------------------------------------------------------

Floating cells (10^5^) were plated in each well of a black 96-well plate on 10 μg/mL fibrinogen with 100 μL of mHBSS buffer in the presence of 10 ng/mL dihydrorhodamine 123. Cells were incubated for 30 min at 37°C/5% CO~2~. PMA was added to a final concentration of 50 ng/mL or vehicle control DMSO was added to samples. Optimal reactive oxygen species production was determined by time course. Fluorescent measurements were taken of samples in triplicate or replicates of four on the Victor^3^ V plate reader (Ex/Em 500/536).

NET Formation {#sec4.11}
-------------

hiPSC or primary blood neutrophils (2^5^) were plated on 12-mm glass coverslips coated with 10 μg/mL fibrinogen and blocked with 2% BSA. Cells were allowed to adhere for 30 min then treated, or not, with 100 nM PMA for 4 h. Assay was stopped with fixation by gentle addition of paraformaldehyde to 4% final concentration for 15 min. Cells were stained with human neutrophil elastase for 1 h in 5% goat serum then stained with Hoechst 33342 for 10 min before mounting. Cells were imaged using an LSM 800 Zeiss Airyscan 60× oil emersion lens.

Statistical Analysis {#sec4.12}
--------------------

All the data reported as mean + SE. All the graphs and statistics were performed using GraphPad Prism software (GraphPad, San Diego, CA).
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